France, June 21 -- New long-acting antiretroviral treatment lenacapavir requires just two injections a year, reducing the need for daily pills. But questions remain over access, cost and whether enough doses will be available to meet demand in the country with the world's largest HIV-positive population.

Ndong Essomba Bitchoka oversees the HIV/AIDS and tuberculosis care unit at the District Deido hospital in Douala, Cameroon.

RFI: South Africans living with HIV can now benefit from lenacapavir. Can you explain how this new treatment works?

Ndong Essomba Bitchoka: Lenacapavir is an antiretroviral drug. It prevents the assembly of the HIV virus's RNA molecules, which stops new HIV viruses from forming. That is essentially how it works. ...